JP2013523817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523817A5 JP2013523817A5 JP2013503826A JP2013503826A JP2013523817A5 JP 2013523817 A5 JP2013523817 A5 JP 2013523817A5 JP 2013503826 A JP2013503826 A JP 2013503826A JP 2013503826 A JP2013503826 A JP 2013503826A JP 2013523817 A5 JP2013523817 A5 JP 2013523817A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- carbon atoms
- alkyl
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- 125000004432 carbon atom Chemical group C* 0.000 claims 27
- -1 3-ethoxy-4-methoxy-phenyl Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 16
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 206010022000 influenza Diseases 0.000 claims 11
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 230000002519 immonomodulatory effect Effects 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 3
- 208000037797 influenza A Diseases 0.000 claims 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 2
- 241001473004 H10N7 subtype Species 0.000 claims 2
- 241000197306 H1N1 subtype Species 0.000 claims 2
- 241000197305 H1N2 subtype Species 0.000 claims 2
- 241000197304 H2N2 subtype Species 0.000 claims 2
- 241000252870 H3N2 subtype Species 0.000 claims 2
- 241001473385 H5N1 subtype Species 0.000 claims 2
- 241000252864 H7N2 subtype Species 0.000 claims 2
- 241000252863 H7N3 subtype Species 0.000 claims 2
- 241000252868 H7N7 subtype Species 0.000 claims 2
- 241001473386 H9N2 subtype Species 0.000 claims 2
- 206010061494 Rhinovirus infection Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000037799 influenza C Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical group OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IMOZEMNVLZVGJZ-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical group C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-UHFFFAOYSA-N 0.000 claims 1
- QDZOBXFRIVOQBR-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical group C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 0 CCN(C(*)*)C(C)=O Chemical compound CCN(C(*)*)C(C)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32180210P | 2010-04-07 | 2010-04-07 | |
| US61/321,802 | 2010-04-07 | ||
| US201161435726P | 2011-01-24 | 2011-01-24 | |
| US61/435,726 | 2011-01-24 | ||
| PCT/US2011/031190 WO2011127019A2 (en) | 2010-04-07 | 2011-04-05 | Methods for treating respiratory viral infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523817A JP2013523817A (ja) | 2013-06-17 |
| JP2013523817A5 true JP2013523817A5 (https=) | 2014-05-22 |
| JP5937060B2 JP5937060B2 (ja) | 2016-06-22 |
Family
ID=44168807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013503826A Active JP5937060B2 (ja) | 2010-04-07 | 2011-04-05 | 呼吸器ウイルス感染症の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9408831B2 (https=) |
| EP (1) | EP2555769B1 (https=) |
| JP (1) | JP5937060B2 (https=) |
| CA (1) | CA2794096A1 (https=) |
| MX (1) | MX341050B (https=) |
| WO (1) | WO2011127019A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105873611A (zh) * | 2013-11-06 | 2016-08-17 | 细胞基因公司 | 利用pde4调节剂治疗病毒性疾病的组合物和方法 |
| GB201504763D0 (en) | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| GB201616439D0 (en) | 2016-09-28 | 2016-11-09 | Mironid Limited | Compounds and uses |
| GB201805527D0 (en) | 2018-04-04 | 2018-05-16 | Mironid Ltd | Compounds and their use as pde4 activators |
| WO2020223608A1 (en) * | 2019-05-02 | 2020-11-05 | Thiolab, Llc, | Inhibition of il-1 and il-6 inflammation |
| EP4132503B1 (en) * | 2020-04-10 | 2026-04-22 | University of Georgia Research Foundation, Inc. | Probenecid for use in the treatment of sars-co-v2 infections |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| WO2022011305A2 (en) * | 2020-07-09 | 2022-01-13 | Beyond Barriers Therapeutics, Inc. | Intranasal administration of an antioxidant compound for treating coronavirus infection |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
| HUP0003761A3 (en) | 1997-07-31 | 2001-04-28 | Celgene Corp Warren | Substituted alkanohydroxamic acids and pharmaceutical compositions containing them |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| TR200101502T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| CN1342146A (zh) | 1999-03-18 | 2002-03-27 | 塞尔基因公司 | 取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途 |
| US6555523B1 (en) * | 1999-07-08 | 2003-04-29 | Patrick T. Prendergast | Use of cirsiliol and derivatives to treat infections |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6436971B2 (en) * | 2000-02-09 | 2002-08-20 | Smithkline Beecham Corporation | Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| NZ540546A (en) * | 2002-11-18 | 2008-03-28 | Celgene Corp | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| KR20070092276A (ko) | 2004-12-13 | 2007-09-12 | 셀진 코포레이션 | Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도 |
| JP2010530870A (ja) * | 2007-06-22 | 2010-09-16 | エーテーツェー チューリッヒ | 抗ウイルス剤 |
| US20110028510A1 (en) * | 2009-02-18 | 2011-02-03 | Combinatorx (Singapore) Pte. Ltd. | Compositions, Methods, and Kits for Treating Influenza Viral Infections |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2011
- 2011-04-05 MX MX2012011547A patent/MX341050B/es active IP Right Grant
- 2011-04-05 JP JP2013503826A patent/JP5937060B2/ja active Active
- 2011-04-05 WO PCT/US2011/031190 patent/WO2011127019A2/en not_active Ceased
- 2011-04-05 US US13/639,848 patent/US9408831B2/en active Active
- 2011-04-05 CA CA2794096A patent/CA2794096A1/en not_active Abandoned
- 2011-04-05 EP EP11714208.3A patent/EP2555769B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523817A5 (https=) | ||
| JP7126947B2 (ja) | 抗ウイルス剤によるｂ型肝炎ウイルスの排除 | |
| EP2725902A2 (en) | Anti-viral combination therapy | |
| WO2017108630A1 (en) | Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor | |
| US10226449B2 (en) | Heterocyclic modulators of lipid synthesis and combinations thereof | |
| JP2009507896A5 (https=) | ||
| AU2015204907B2 (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
| JP2022511819A (ja) | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染症を治療する方法 | |
| JP7460772B2 (ja) | コロナウイルス感染症の治療方法 | |
| WO2007139150A1 (ja) | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 | |
| US10428041B2 (en) | Pyridyl reverse sulfonamides for HBV treatment | |
| US20230248712A1 (en) | Methods and compositions for treating rna viral infections | |
| EP2536411A2 (en) | Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals | |
| KR20250169632A (ko) | 지질 합성의 헤테로사이클릭 조절인자 | |
| EP3402477A2 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| US9433592B2 (en) | Pharmaceutical or veterinary antiviral compositions | |
| WO2016086153A2 (en) | Use of tetrahydro!ndazolylbeimzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) | |
| US9096585B2 (en) | Antiviral compounds and uses thereof | |
| WO2015134525A1 (en) | Antiviral axin stabilizer | |
| US9365523B2 (en) | Imidazolyl amide compounds and uses related thereto | |
| TW202203914A (zh) | 特別用於治療b型肝炎和d型肝炎之抗病毒化合物 | |
| WO2018222975A1 (en) | Methods for the treatment of cancer | |
| EP4337323A1 (en) | Bicyclic heterocyclic compounds for prophylaxis and treatment of viral infections | |
| JP2013509420A (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン重水素化合物 | |
| WO2006095624A1 (ja) | プロテアーゼインヒビター |